生物制剂及其输送系统：心肌梗死的趋势。
Biologics and their delivery systems: Trends in myocardial infarction.
机构信息
Department of Chemical Engineering, University of Pittsburgh, 940 Benedum Hall, 3700 O'Hara Street, Pittsburgh, PA 15213, USA.
Starzl Transplantation Institute, 200 Darragh St, Pittsburgh, PA 15213, USA; Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; Department of Immunology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
出版信息
Adv Drug Deliv Rev. 2021 Jun;173:181-215. doi: 10.1016/j.addr.2021.03.014. Epub 2021 Mar 26.
Cardiovascular disease is the leading cause of death around the world, in which myocardial infarction (MI) is a precipitating event. However, current therapies do not adequately address the multiple dysregulated systems following MI. Consequently, recent studies have developed novel biologic delivery systems to more effectively address these maladies. This review utilizes a scientometric summary of the recent literature to identify trends among biologic delivery systems designed to treat MI. Emphasis is placed on sustained or targeted release of biologics (e.g. growth factors, nucleic acids, stem cells, chemokines) from common delivery systems (e.g. microparticles, nanocarriers, injectable hydrogels, implantable patches). We also evaluate biologic delivery system trends in the entire regenerative medicine field to identify emerging approaches that may translate to the treatment of MI. Future developments include immune system targeting through soluble factor or chemokine delivery, and the development of advanced delivery systems that facilitate the synergistic delivery of biologics.
心血管疾病是全球范围内的主要死亡原因，其中心肌梗死（MI）是一个促成事件。然而，目前的治疗方法并不能充分解决 MI 后多个失调的系统。因此，最近的研究已经开发出新型的生物传递系统，以更有效地解决这些疾病。本综述利用最近文献的科学计量学总结，确定了旨在治疗 MI 的生物传递系统的趋势。重点放在从常见的传递系统（例如微颗粒、纳米载体、可注射水凝胶、可植入贴片）中持续或靶向释放生物制剂（例如生长因子、核酸、干细胞、趋化因子）。我们还评估了整个再生医学领域的生物传递系统趋势，以确定可能转化为 MI 治疗的新兴方法。未来的发展包括通过可溶性因子或趋化因子传递进行免疫系统靶向，以及开发促进生物制剂协同传递的先进传递系统。
Zotero 插件